TMPRSS2 and prostate neoplasm: Although TMPRSS2–ERG fusion has typically been reported as prevalent in 40–50% of prostate tumours, the range has varied by as much as 25–60% (Nam et al, 2007; Setlur et al, 2008; Sun et al, 2008; Yoshimoto et al, 2008; Hofer et al, 2009; Mosquera et al, 2009).